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ABSTRACT 
Purpose 
Mitochondrial DNA (mtDNA) depletion syndrome (MDDS) encompasses a group of genetic 
disorders of mtDNA maintenance. Mutation of RRM2B is an uncommon cause of infantile-
onset encephalomyopathic MDDS. Here we describe the natural history of this disease. 
Methods 
Multinational series of new genetically confirmed cases from six paediatric centres. 
Results  
Nine new cases of infantile-onset RRM2B deficiency, and 22 previously published cases 
comprised a total cohort of 31 patients. Infants presented at a mean of 1.95 months with 
truncal hypotonia, generalised weakness and faltering growth. Seizures evolved in 39% at a 
mean of 3.1 months. Non-neurological manifestations included respiratory distress/failure 
(58%), renal tubulopathy (55%), sensorineural hearing loss (36%), gastrointestinal 
disturbance (32%), eye abnormalities (13%), and anaemia (13%). Laboratory features 
included elevated lactate (blood, CSF, urine, MR spectroscopy), ragged-red and cytochrome 
c oxidase-deficient fibres, lipid myopathy and multiple oxidative phosphorylation enzyme 
deficiencies in skeletal muscle. Eight new RRM2B variants were identified. Patients with 
biallelic truncating variants had the worst survival. Overall survival was 29% at 6 months and 
16% at 1 year. 
Conclusion 
Infantile-onset MDDS due to RRM2B deficiency is a severe disorder with characteristic 
clinical features and extremely poor prognosis. Presently management is supportive as there 
is no effective treatment. Novel treatments are urgently needed. 
[200/200 words]  
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INTRODUCTION 
 
RRM2B (OMIM 604712) is a nuclear gene encoding the small p53 inducible subunit (p53R2) 
of the ribonucleotide reductase (RNR) complex. RNR is a heterotetramer1-3 composed of two 
R1 subunits (encoded by RRM1), and two R2 (encoded by RRM2) or p53R2 (encoded by 
RRM2B) subunits. RNR localises to the cytosol4 and reduces ribonucleotide diphosphates to 
deoxyribonucleotide diphosphates which is important in keeping the mitochondrial 
deoxyribonucleotide triphosphate (dNTP) pool replete. These dNTPs are then thought to be 
relocated to the nucleus and mitochondria for DNA synthesis.  
 
Unlike nuclear DNA, which replicates during the S phase of the cell cycle before mitosis, 
mtDNA is synthesised throughout the non-proliferative phase (G0) and thus requires a steady 
pool of dNTPs. Therefore, RNR exists in two forms: that which supports de novo dNTP 
synthesis during the S phase (composed of 2R1, 2R2 subunits) and that which is responsible 
for maintenance of dNTP pools in G0 (composed of 2R1, 2p53R2). p53 is a tumour 
suppressor gene which is activated during DNA damage. p53R2 is thought to have two roles: 
provision of dNTPs for DNA repair following nuclear DNA damage2 and also a 
‘housekeeping role’ in maintaining dNTP pools needed for mtDNA replication throughout 
the cell cycle in both dividing and non-dividing cells5,6. 
 
Mitochondrial DNA depletion syndrome (MDDS) encompasses a group of nuclear gene 
disorders affecting key enzymes involved in the synthesis of mtDNA and its replication. This 
includes several genes involved in either mtDNA replication itself or in the synthesis of 
nucleosides which are incorporated into mtDNA at the replication fork7,8. MDDS is 
classically categorised into different phenotypic subtypes, each with an expanding number of 
causative disease genes. These phenotypes are: myopathic (caused by mutations in TK2, 
5 
 
SLC25A4, MGME1), encephalomyopathic (RRM2B, FBXL4, ABAT), hepatocerebral (TFAM, 
MPV17, DGUOK, SUCLA2, SUCLG1), Alpers syndrome (POLG, TWNK) and MNGIE 
(TYMP, rarely POLG and RRM2B)6-9. Mutations of RRM2B may be associated with several 
different phenotypes, including infantile-onset MDDS caused by autosomal recessive 
inheritance of biallelic pathogenic variants3,5,10-16. Other phenotypes include multiple mtDNA 
deletions in children and adults which are caused by either autosomal recessive inheritance of 
biallelic pathogenic variants or autosomal dominant inheritance of a single pathogenic 
variant17-21, Kearns-Sayre syndrome19, Mitochondrial Neurogastrointestinal Encephalopathy 
(MNGIE) 22 and, most recently, acute liver failure23. 
 
We describe nine new cases of infantile-onset encephalomyopathic RRM2B MDDS, reporting 
their detailed phenotype, investigations, treatment and outcome. Taken together with a further 
22 published cases, we describe the natural history of 31 patients with infantile RRM2B 
deficiency. 
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METHODS 
Patient cohort 
Nine new patients were recruited from three British centres, two centres in USA and one 
French centre. Patients were included if they had confirmed biallelic RRM2B variants and an 
infantile-onset clinical phenotype, and were not previously published. Data were collected 
retrospectively by clinicians in each centre using a standardised questionnaire. This study was 
approved by Great Ormond Street Hospital (GOSH) as a clinical audit.  
Molecular studies in new patients  
MtDNA copy number relative to nuclear DNA was estimated and compared with age-
matched normal controls by real-time quantitative PCR24. For the UK cases, this was 
performed as described previously except that the nuclear DNA probe was labelled with Vic 
and the assays were performed simultaneously using a PE7500 real-time PCR instrument 
(Applied Biosystems, Foster City, CA, USA). All exons and exon-intron boundaries of 
RRM2B (GenBank accession number NM_015713.4, exons 1-9 numbered sequentially) were 
Sanger sequenced using capillary electrophoresis in a 3730 DNA Analyzer (Applied 
Biosystems, Foster City, CA, USA). For probands in whom Sanger sequencing only 
identified a single heterozygous pathogenic variant, RRM2B exon copy number was assessed 
by multiplex ligation-dependent probe amplification (SALSA MLPA P089-B1, MRC-
Holland, Amsterdam, The Netherlands). For two cases, genetic diagnoses were obtained by 
genome sequencing in a rapid genome sequencing project for critically ill infants25. For a 
further case, the causal RRM2B variants were identified by exome sequencing as previously 
described26. 
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Literature Search 
We collected data from all published cases of infantile-onset RRM2B-related MDDS by 
searching PubMed for relevant publications. Search terms were ‘RRM2B’ OR 
‘ribonucleotide reductase’ OR ‘p53R2’ with filters for English language publications and 
human species (search completed 21 October 2018). This yielded 1948 publications including 
10 papers containing relevant cases.  
 
Statistical Analyses 
Stata software version 15 was used for all statistical analyses (https://www.stata.com/).  A P 
value <0.05 was considered statistically significant. 
 
Modelling 
FoldX server was used to model the new missense variants27. 
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RESULTS  
Patient cohort 
Nine previously unreported cases are included in our multinational cohort (patients A-I). 
They presented with symptoms at an average of 2.3 months (range 0 – 4 months). Twenty-
two further cases were identified from the literature (patients 1-22), making a total of 31 
cases of infantile-onset RRM2B-deficient MDDS3,5,10-16.  
 
Molecular analyses 
Mitochondrial DNA studies 
Residual mtDNA levels in skeletal muscle in the new cohort of 9 previously unreported 
infants with biallelic RRM2B variants ranged from 2 to 20% (median 4.5%) which is far 
below the accepted diagnostic limit of 30% for MDDS28. 
 
Novel pathogenic RRM2B variants 
We identified eight novel pathogenic RRM2B variants not present in the Gnomad database 
(https://gnomad.broadinstitute.org/gene/ENSG00000048392). These are c.599G>A 
p.Gly200Glu, c.313G>A p.Glu105Lys, c.181G>C p.Ala61Pro, c.165G>A p.Met55Ile, 
c.(321+1_322-1)_(684+1_685-1)del (exon 4-6 deletion), c.635_636insAAG 
p.Gly212_Leu213insSer, c.400C>G p.His134Asp and c.59C>G p.Ser20*. The six missense 
and insertion variants are found in amino acid positions with a high degree of evolutionary 
conservation across species (Clustal Omega, [http://www.clustal.org/], see Supplementary 
Figure 1 for alignments, Figure 1a and Supplementary Figure 2 for the biallelic variants 
identified in the cohort); at these positions, the amino acids of the human sequence are also 
shared by 65-96% of RRM2B orthologues (n=150 orthologues; data from Consurf).  
The six non-truncation variants are distributed across the N-terminal two-thirds of the 
RRM2B protein, a 351-residue polypeptide (Figure 1b). The crystal structure of human 
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RRM2B reveals a homodimer with an active site di-iron cofactor from each monomer1. Two 
variants, p.Ala61Pro and p.Gly200Glu, result in marked changes to the amino-acid side-
chains, and are predicted by the FoldX server to reduce protein stability (ΔΔG 3.97 and 11.60 
kcal/mol respectively). His134 is one of the iron ligating residues in the structure, hence the 
p.His134Asp variant likely interferes with metal binding, and is also predicted by FoldX to 
reduce protein stability (ΔΔG 6.50 kcal/mol). Glu105 is located at the dimer interface, 
forming salt bridges with Arg40 and Arg121 from the opposite dimer subunit. The 
p.Glu105Lys variant could therefore interfere with structural integrity of the homodimer. The 
p.Met55Ile and p.Gly212_Leu213insSer variants are located at the protein exterior, away 
from the core active centres; the effects of these substitutions are less clear from the structure. 
 
Disease course of nine new cases 
The disease phenotype was multisystemic, with an initial myopathic presentation followed by 
evolution of respiratory distress and failure leading to assisted ventilation in all cases. 
Multisystem involvement included the neurological, renal, cardiac, respiratory, 
gastrointestinal and haematological systems, the eyes, hearing and growth. Table 1 and 
Figure 2 detail the biochemical and histological findings. Supplementary Figure 3 illustrates 
the neurological, respiratory, renal and gastrointestinal features and growth of the 9 new 
cases. Supplementary Figure 4A-C illustrate the treatments administered to the new cases, 
including respiratory support, supportive feeding and cofactor supplementation. 
Supplementary Figure 4D illustrates the survival outcomes for the new cases. By 6 months 
8/9 patients had already developed respiratory failure and 6/9 had died. All nine patients died 
by 22 months. The causes of death are illustrated in Supplementary Figure 4E.  
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Natural history of cohort of 31 patients 
Considering the entire cohort of 31 infants with RRM2B deficiency, median age of symptom 
onset was 2 months (mean 1.95 months, range 0-6 months).  The most frequent presenting 
features were muscular hypotonia, feeding difficulty, failure to thrive, hearing loss and 
respiratory distress. The clinical phenotype was multisystemic. Neurological involvement 
occurred in all cases: encephalopathy in 15/31 (48%), seizures in 12/31 (39%) presenting at 
an average age of 3.1 months (range 20 days-7 months), respiratory involvement in 18/31 
(58%), renal involvement in 17/31 (55%), growth abnormalities in 16/31 (51%), hearing loss 
in 11/31 (36%), GI involvement in 10/31 (32%), eye abnormalities in 4/31 (13%), and 
anaemia in 4/31 (13%) of cases.  The most consistent biochemical abnormality was elevated 
lactate seen in blood, CSF and urine, followed by elevated alanine and mildly elevated 
creatine kinase. The most frequent skeletal muscle histopathological features were COX-
deficient fibres, abnormal lipid deposition and ragged-red fibres. The most frequent 
OXPHOS biochemical abnormalities in muscle were decreased activities of complexes I, III 
and IV with compensatory increases in both complex II and citrate synthase activities. 
Neuroimaging most frequently showed a structurally normal brain, and less frequently 
evidence of demyelination, white matter abnormality or generalised atrophy (Table 2). 
Elevated lactate peak was frequently observed on MR spectroscopy. Detailed clinical, 
biochemical and radiological features of all 31 cases are summarised in Table 2.  
 
Survival outcomes for the cohort were poor. A Kaplan-Meier survival curve of all 31 cases of 
RRM2B-associated infantile MDDS (Figure 3) shows that survival at 3 months was 64.5% 
(20/31), at 6 months 29% (9/31), at 1 year 16% (5/31) and at 2 years 6% (2/31). 
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Phenotypic correlations  
Mitochondrial DNA content  
Patients with lower residual mtDNA levels in skeletal muscle tended to die earlier, however 
this observation did not meet statistical significance (Spearman rank test p=0.06). There was 
no statistically significant correlation between residual mtDNA content and age of onset 
(Spearman rank test p = 0.44) or number of organ systems affected (Spearman rank test p 
=0.14). We compared patients who developed seizures (12/31) as a subgroup to patients who 
did not develop seizures (19/31) and noted no difference in average mtDNA levels between 
these two groups (Mann Whitney U test p = 0.85). Similarly, we noted no significant 
difference in average residual mtDNA levels in patients who developed renal disease (n=17) 
compared to those who did not develop renal disease (n=14) (Mann Whitney U test p = 0.29).  
 
Age of onset of symptoms  
Infants presenting earlier appeared to die earlier, however, this did not reach statistical 
significance (Spearman rank test, p= 0.07). There was no correlation between age of onset 
and number of organs affected (Spearman rank test, p=0.20, nor between age of onset and 
development of seizures (Mann Whitney U test p= 0.88). Interestingly patients who 
developed renal disease presented earlier (median age of onset for patients who developed 
renal disease was 2 months vs 3 months for those without renal disease, Mann Whitney U test 
p=0.01*).  
 
Age of death  
There was no correlation between age of death and number of organs affected (Spearman 
rank test p=0.42), nor between age of death and occurrence of seizures (Mann Whitney U test 
p=0.56). Patients with renal disease tended to die earlier, however this did not reach statistical 
significance (Mann Whitney U test p= 0.07). 
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Genotype-phenotype correlations  
Patients were divided into two groups based on genotype. Group 1 included 7 patients whose 
pathogenic variants are expected to result in the formation of only truncated mRNA which is 
likely to be subject to nonsense mediated decay (5 with biallelic nonsense variants [patients 
1-3, 21, 22], one with biallelic frameshift variants [patient 19], and one compound 
heterozygote with a nonsense variant and a splice site variant [patient I]). Group 2 patients 
included the remaining 24 patients whose variants are not expected to result in the formation 
of solely truncated mRNA (15 patients with biallelic missense variants [patients A,B,D,G,H, 
6,8,11,13-18,20], 3 compound heterozygotes with a missense variant and a splice site variant 
[patients 4,5,12], 3 compound heterozygotes with a missense variant and a truncating variant 
[patients C, 9,10], 2 patients with biallelic in-frame insertions [patients E,F], and one 
compound heterozygote for a missense variant and an in-frame deletion [patient 7]). 
 
Group 1 patients had a worse prognosis than group 2. Median age of death was 2.5 months 
for group 1 compared to 5 months for group 2 (Mann Whitney U test p=0.002**). There was 
no statistically significant difference between age of onset or number of organs affected 
between the two groups (Mann Whitney U test p=0.33 and 0.16 respectively), nor any 
correlation between genotypic group and development of seizures (Chi squared test, p=0.53) 
or renal disease (Chi squared test, p=0.31). 
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DISCUSSION 
Here we have shown that infantile MDDS due to biallelic RRM2B variants presents in the 
very first months of life with hypotonia, poor feeding, and faltering growth leading to 
hospitalisation. Elevated blood and CSF lactate may be the clue to an underlying 
mitochondrial disease, prompting multi-system assessment revealing involvement of other 
organs, frequently including SNHL and renal tubulopathy/nephrocalcinosis. Infants may also 
develop GI symptoms such as recurrent vomiting/reflux. All deteriorate with respiratory 
insufficiency/failure leading to assisted ventilation. Generalised seizures may develop later in 
the disease course. This infantile clinical phenotype is distinct from paediatric and adult-onset 
disease associated with multiple mtDNA deletions due to recessive (biallelic) and dominant 
(heterozygous) RRM2B variants, where PEO, ptosis and proximal muscle weakness are the 
most frequent features and encephalopathy, gastrointestinal and renal involvement are 
uncommon.21 Interestingly, SNHL loss is present to the same degree (36% of infantile-onset 
MDDS and 36% of cases with paediatric/adult-onset disease).  
 
Although we have shown that the phenotype of infantile MDDS due to RRM2B deficiency is 
relatively homogeneous, we did observe some phenotypic heterogeneity within the cohort. 
Notably, although MDDS due to RRM2B deficiency is classically described as 
encephalomyopathic6, encephalopathy was seen in 15/31 cases (49%) and seizures were 
observed in only 12 infants (39%). It is possible that some patients died due to severe 
myopathy before the development of encephalopathy or indeed that they would never have 
developed encephalopathy. Incomplete penetrance of neurological features is seen in other 
genetic causes of MDDS e.g. infantile-onset DGUOK deficiency where individuals may 
develop liver disease which can be fatal, or go on to develop multisystemic disease with 
additional brain involvement including encephalopathy. Conversely in our cohort, renal 
tubulopathy was seen in 17/31 (55%) of cases, and SNHL in 12/31 (39%). The high 
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incidence of renal tubulopathy in infants with MDDS is reminiscent of the phenotype of the 
rrm2b-/- exon 3 and 4 deletion mouse model in which renal failure is the most prominent 
feature and cause of death29. 
 
Mutational analysis of the new patients in our cohort revealed that several variants seen in 
patients with infantile MDDS have also been seen in children and adults with multiple 
mtDNA deletions presenting with PEO and myopathy. This confirms previous reports 
suggesting that missense variants may behave recessively (homozygous or compound 
heterozygous) as well as in a heterozygous dominant negative manner in different 
individuals. The presence of normal p53R2 protein in cases of heterozygosity may not always 
rescue the presence of mutated p53R2, owing to a dominant negative effect which may be 
mediated by disruption of normal allosteric interactions between the heterotetrameric 
subunits of the RNR complex21. 
 
In this study we sought to determine whether there are any phenotypic and genotype-
phenotype correlations in RRM2B-associated MDDS. This is important for prognostication 
for affected infants and in future may enable assessment of suitability for candidate therapies. 
As MDDS is defined as residual mtDNA <30% of age-matched healthy controls, all of the 
patients met this criterion28. In this natural history study, we investigated whether mtDNA 
quantification can be used not just in diagnosis but also in predicting severity of disease. As it 
was not possible to apply a specific scoring system, for example the Newcastle Paediatric 
Mitochondrial Disease Scale (NPMDS), in entirety to each patient, the markers of severity of 
disease that we analysed in this study were age of onset, presence of seizures, number of 
organs affected and survival. Taken pairwise, no statistically significant correlation was seen 
between these markers of disease severity and mtDNA quantification. Nevertheless, 
important trends were revealed: earlier disease onset tended to be associated with presence of 
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renal disease later in the disease course and an earlier mortality. While there was no statistical 
correlation between the presence of seizures and age of death, for the 12 patients in the cohort 
who did develop seizures, death followed after an average of 2.9 months (median 1.2 months, 
range 0-15 months) after the appearance of seizures, defining a point of significant clinical 
deterioration in the disease course. Therefore, we suggest that the presence of seizures 
indicates significant brain involvement and therefore severe disease. 
 
When we grouped patients into two variant subgroups we found that patients with biallelic 
variants resulting in truncated transcripts had a relatively shorter survival compared to 
patients with missense/in-frame insertion/deletions resulting in formation of mRNA 
transcripts that are aberrant but not subject to degradation by cellular nucleases. This finding 
was statistically significant despite a small cohort and is consistent with our findings for other 
natural history studies in mitochondrial disease30. 
 
It should be noted that there is a limitation of using age of death as a marker of disease 
severity since in some cases death followed redirection of care after recognising futility of 
treatment. Severe disease may paradoxically be associated with a longer than expected 
lifespan, owing to prolonged artificial ventilation. Another consideration is that meaningful 
correlation between percentage mtDNA levels and genotype based on protein truncation 
could not be determined due to small numbers. Finally, it is assumed that the formation of 
truncated mRNA will result in mRNA degradation and therefore little enzyme activity. 
However, an exception to this has been demonstrated in myocytes of adult patients with exon 
9 deletions where mRNAs escaped nonsense mediated decay and western blots showed 
persistent presence of truncated protein17. 
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We have demonstrated that patients with biallelic variants resulting in truncated mRNA 
transcripts have the poorest prognosis overall. This is an important finding in terms of 
prognostication and appears to be the most robust genotype-phenotype correlation. The 
prognosis overall however is extremely poor, with a 6-month survival of 29% and a one-year 
survival of 16%, underscoring the need to find new effective treatments. 
 
In RRM2B deficiency, inability to reduce ribonucleotide diphosphates to 
deoxyribonucleotide diphosphates (dNDPs) results in mtDNA depletion. For a different form 
of myopathic MDDS, thymidine kinase 2 (TK2) deficiency, it has been proposed that 
bypassing the defective step of nucleoside salvage by supplementation with 
deoxyribonucleotides may represent a therapeutic strategy for MDDS. This has been trialled 
in tk2-deficient mice with some success. A combination of orally supplemented 
deoxycytidine monophosphate (dCMP) and deoxythymidine monophosphate (dTMP) 
delayed disease onset and prolonged survival but did not prevent death in a knock-in model 
of tk2 deficiency31. Deoxyribonucleotide monophosphates appeared able to cross the 
immature blood-brain barrier before P13 but further development of the blood-brain barrier 
after P13 was likely to account for CNS disease at P29 and ultimate death despite therapy. 
Similar results were seen with oral supplementation with deoxycytidine (dC) and 
deoxythymidine (dT) in mice with tk2 deficiency, which is thought to be due to 
compensatory upregulation of the cytosolic enzymes tk1 and dck32. For RRM2B deficiency, 
in vivo studies using a suitable animal knockout model are yet to be undertaken, since the 
existing animal model does not effectively recapitulate human disease29.  
 
For RRM2B deficiency, in vitro studies of supplementation with deoxynucleosides in 
cultured human cells yielded contradictory results. RRM2B deficient patient fibroblasts do 
not express mtDNA depletion in culture unless they are exposed to ethidium bromide or 
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prolonged serum starvation33. Deoxynucleoside supplementation increased intracellular 
dNTP pools and normalized mtDNA synthesis in ethidium bromide treated quiescent patient 
fibroblasts harbouring a lethal homozygous missense RRM2B variant34. However, in a second 
study, supplementation with deoxynucleotide monophosphates (dNMPs) in cultured 
myotubules/myoblasts from another patient was ineffective in restoring mtDNA copy 
number35. In-vivo delivery of all four deoxyribonucleosides via any route has not been 
investigated in any model of MDDS. Furthermore, the CNS penetrance of systemically 
delivered deoxyribonucleosides in humans is unknown. The half-life of adenosine is 
extremely brief when delivered intravenously and there is a risk of toxicity since adenosine 
induces atrioventricular node blockade. It is clear that in the presence of many unknowns, 
detailed pharmacodynamic, pharmacokinetic and efficacy studies in a knock-out animal 
model of RRM2B deficiency which effectively recapitulates neurological disease seen in 
humans will be essential to answer these questions.  
 
Prior to designing a clinical trial for an experimental treatment for RRM2B-related infantile 
MDDS in humans, it will be necessary to determine at which time point CNS involvement is 
considered irreversible. This should consider both the natural history of disease in humans 
and the optimal timepoint for effective drug delivery in preclinical drug trials using an 
appropriate animal model. Difficult decisions will need to be made in the advent of 
experimental therapies as to whether a specific patient is deemed to have reversible disease, 
especially since conventional neuroimaging is often normal early on in infants who have 
quite severe functional neurodisability, and seizures are not universally seen. However, in 
cases for which there are structural abnormalities on neuroimaging or prolonged/refractory 
electrical or clinical seizures, we suggest that CNS disease has progressed beyond the point 
of reversibility.  
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Whether or not irreversible disease should be treated with an experimental treatment ought to 
be considered on a case-by-case basis utilising existing ethical frameworks. This is predicated 
on determining whether the disease modifying treatment is likely to improve the quality of 
life rather than just prolonging life. The Royal College of Paediatrics and Child Health have 
provided an ethical framework which states that the best interests of the child need to be 
considered to ‘determine whether or not there is an overall benefit in prolonging life because 
of the adverse impact entailed’36. The ethical implications of prolonging life with long term 
ventilation in the context of commencement of an experimental therapy need to be weighed 
carefully against those of redirection of supportive care. Indeed, long term ventilation may be 
requested as a bridge to emerging or experimental therapies and its use in this setting is 
difficult to evaluate37. An ethics committee should be called upon to meet to assess the 
individual clinical case considering the opinion of the infant’s parents and available second 
opinions provided by other clinical teams. 
 
It is clear that the natural history of infantile-onset RRM2B MDDS is characterised by rapid 
neurological disease progression. Prompt diagnosis is essential for optimal management of 
these infants, particularly avoidance of prolonged invasive ventilation as currently there are 
no effective disease-modifying therapies for this and most other mitochondrial diseases38. In 
future, if a clinical trial of a disease-modifying therapy is to be undertaken, clinical and 
ethical discussions regarding suitability for trial recruitment of the affected infant need to 
commence soon after a genetic diagnosis is made.  
 
To facilitate more rapid diagnosis, we suggest that where there is a high index of clinical 
suspicion indicated by a combination of several of the following six features: hypotonia 
developing insidiously after birth, renal tubulopathy, sensorineural hearing loss, feeding 
difficulty, muscle weakness and respiratory failure, targeted single gene sequencing for 
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RRM2B should be prioritised over muscle biopsy and exome sequencing. Where the index of 
clinical suspicion is lower, that is when only a few of these features are present, the 
differential diagnosis includes potentially treatable disorders such as spinal muscular 
atrophy12, benign reversible infantile respiratory chain deficiency disorders39, congenital 
myopathies and other causes of MDDS e.g. TK2 deficiency. In this scenario a rapid exome 
sequencing approach with consideration of early muscle biopsy is more appropriate. Of note, 
creatine kinase levels are normal or only mildly elevated in RRM2B deficiency effectively 
distinguishing this disorder from myopathic MDDS due to TK2 deficiency40. 
 
CONCLUSIONS  
Infantile-onset RRM2B-related MDDS should be suspected in cases where mtDNA depletion 
has been demonstrated in an infant with a combination of encephalomyopathy, respiratory 
failure, and renal or hearing impairment. The majority of infants are already symptomatic 
with hypotonia and faltering growth well before presentation with respiratory failure to 
emergency medical services. The disease evolves relentlessly with a one-year survival of 
16%. Biallelic truncating variants predict the worst survival outcome. Whilst awaiting a 
genetic diagnosis there is evolving brain injury, implying a narrow therapeutic window for 
treatment with disease-modifying therapies, should these become available. The usefulness of 
deoxyribonucleoside supplementation remains to be elucidated in an animal model that 
adequately recapitulates human neurological disease before considering clinical trials in 
humans.  
[3978/4000 words] 
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Patient 
Highest serum 
Lactate 
Lactate: 
pyruvate 
ratio 
CSF lactate 
Creatine 
Kinase 
Free 
carnitine 
Acylcarnitines 
Plasma amino 
acids 
Urinary Organic Acids Complex I* Complex II* Complex III* Complex II+III* Complex IV* 
Citrate 
Synthase† 
Mt DNA‡ 
A 7 ND ND 1209 (<170) ND ND Normal 
Increased lactate, 4-OH-
phenyllactate, 4-OH-
phenylpyruvate, Kreb cycle 
intermediates, 3OHB 
13% 16% 16% ND 16% 234% ND 
B 4.6 38 3.5 330 (<145) 93 (14-53) 
Global mildly 
increased 
acylcarnitines,hy
droxyacyl-
carnitines 
Raised alanine 
and glycine. 
Decreased 
serine, valine, 
cysteine 
Increased lactate, 4-OH-
phenyllactate, succinate, 
benzoate, mildly increased 
3OHB, adipate, suberate 
4  
(12-29) 
33%  
112  
(23-49)  
228% † 
 
43  
(223-454) 
19%  
 
ND 
10  
(114-250)  
8% 
377  
(82-150) 
550% 
6% 
C 3.2 ND ND 361(<400) 37 (13-80) Normal Normal 
Strong lactate, moderate 
pyruvate, fumarate, citrate, 
malate, mild 2OH valerate, 
3OHB, 2OHB 
0.087  
(0.104- 0.268) 
83% 
ND ND 
0.061  
(0.04-0.204) 
100% 
0.005  
(0.014-0.034) 
35% 
ND 5% 
D 5 ND ND 91 (<240) ND Normal Normal Variably raised fumarate 
0.004  
(0.104-0.268) 
3.8% 
ND ND 
0.005  
(0.04-0.204) 
12.5% 
0.001  
(0.014-0.034) 
7% 
ND 20% 
E 5.7 ND 5.6 546 (<204) ND Elevated C2 Normal 
Slightly increased lactate, 
fumarate, malate 
ND ND ND ND ND ND ND 
F 6.1 ND ND 340 <374) 31.6 (21-53) Normal Raised alanine 
Markedly increased 3OHB, 
moderate lactate, pyruvate, 
fumarate, malate, aconitate, 
citrate, Mild 2- ethyl 
hydracrylate. 
ND ND ND ND ND ND 4% 
G 8.2 54 3.3 220 (<400) 35 (13-80) 
Mildly raised 
malonyl-
carnitine 
Raised alanine 
Grossly raised lactate, 
pyruvate, 2OHB, fumarate, 
citrate, 4OHphenyllactate, 
4OHphenylpyruvate, 3OHB, 
3OHISV 
0.018  
(0.104-0.268) 
17.3% 
ND ND undetectable undetectable ND 6% 
H 7.4 7.4 4.7 292 (<200) Normal Normal Raised alanine Normal 
0.006 
(0.068-0.14) 
8.8% 
0.08 
(0.098-0.192) 
81.6% 
0.046  
(0.209-0.899) 
22% 
ND 
0.031  
(0.613-1.635) 
5% 
ND 3% 
I 41.7 ND 2 223 (<400) 17 (13-80) Normal Raised alanine 
Grossly elevated lactate, 
pyruvate, moderated 2OHB, 
mildly 2OH valerate, 2 
oxoisocaproate, 3MGA, 3OH 
adipate, 4OH phenyllactate 
0.127  
(0.104-0.268) 
100% 
ND ND 
0.025  
(0.04-0.204) 
62.5% 
0.002  
(0.014-0.034) 
14% 
ND 2% 
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Table 1: Biochemical parameters observed in 9 new cases of RRM2B deficiency.  
Abbreviations: MGA: methylglutaconate, OH hydroxy, OHB hydroxybutyrate, ND Not done. 
Units: lactate and CSF lactate: mmol/L, CK: U/L, free carnitine: umol/L. Normal range for 
serum lactate <2mmol/L and for CSF lactate <2.2mmol/L. Other reference ranges are included 
in parentheses. * % of the lower reference range value, † % of the higher reference range value, 
‡ % of age matched control values. 
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Biochemical Features Number of patients 
during clinical course 
General Biochemistry  
Hyperlactataemia 31/31(100%) 
Elevated lactate/pyruvate ratio 4/5 (80%) 
Elevated CSF lactate 8/10 (80%) 
Elevated creatine kinase 8/19 (42%) 
Low free carnitine 3/11 (27%) 
Plasma amino acids 
Elevated alanine 
Elevated branched chain amino 
acids 
Multiple low species 
Normal 
 
10/16 (63%) 
4/16 (25%) 
3/16 (19%) 
4/16 (25%) 
Urine organic acids 
Elevated lactate 
Elevated pyruvate 
Elevated ketones 
Elevated Krebs cycle intermediates 
Normal 
 
12/16 (75%) 
5/16 (31%) 
7/16 (43%) 
6/16 (38%) 
3/16 (19%) 
Hypocalcaemia 2/31 (6%) 
    
Skeletal muscle spectrophotometry Low 
 
Normal High 
 
Complex I 17/18 1/18 0/18 
Complex II 3/13 2/13 8/13 
Complex III 7/7 0/7 0/7 
Complex IV 20/20 0/20 0/20 
Complex V 3/6 1/6 2/6 
Complex I+III 4/4 0/4 0/4 
Complex II+III 9/11 2/11 1/11 
Citrate synthase 1/13 4/13 8/13 
  
Muscle Histopathology  
Ragged-red fibres 12/19 
Increased SDH  7/19 
COX deficient fibres 16/19 
Lipid storage 14/19 
Atrophic fibres 2/19 
  
Radiological Features  
MRI Head  
Generalised hypo/ 
demyelination 
1/14 
White matter abnormalities 2/14 
Generalised atrophy 2/14 
Normal 9/14 
MR Spectroscopy  
Elevated lactate 
Localisation:  
Basal ganglia 
White matter 
CSF 
Not stated 
8/10 
 
5/8 
3/8 
1/8 
3/8 
Reduced choline/NAA 1/10 
Normal 2/10 
Clinical features Number of patients during clinical 
course 
Neuromuscular system 31/31(100%) 
Truncal hypotonia 30/31 (96.7%) 
Encephalopathy 15/31 (48.4%) 
Gross motor delay 15/31 (48.4%) 
Feeding difficulty 14/31 (45.2%) 
Seizures 12/31 (38.7%) 
Lack of head control 12/31 (38.7%) 
Generalised weakness 10/31 (32.2%) 
Loss of reflexes 9/31 (29%) 
Discoordinated suck 9/31 (29%) 
Ptosis 6/31 (19.3%) 
Progressive external 
ophthalmoplegia 
6/31 (19.3%) 
Discoordinated Swallow  6/31 (19.3%) 
Peripheral neuropathy 2/31 (6.5%) 
Nystagmus  1/31 (3.2%) 
Dystonia 1/31 (3.2%) 
Respiratory system 18/31 (58%) 
Respiratory distress 17/31 (54.8%) 
Respiratory failure 15/31 (48.4%) 
Pneumonia 5/31 (16.1%) 
Renal system 17/31 (54.8%) 
Tubulopathy 16/31 (51.6%) 
Aminoaciduria 7/31 (22.5%) 
Glycosuria 5/31 (16.1%) 
Microalbuminuria 3/31 (9.7%) 
Elevated RBP/Cr 3/31 (9.7%) 
Calciuria 2/31 (6.5%) 
Elevated NAG/Cr  3/31 (6.5%) 
Phosphaturia 1/31 (3.2%) 
Nephrocalcinosis 6/31 (19.3%) 
Auditory system 11/31 (36%) 
Sensorineural hearing loss 11/31 (36%) 
Gastrointestinal system 10/31 (32%) 
Recurrent vomiting 7/31 (22.5%) 
Feed intolerance 3/31 (9.7%) 
Chronic diarrhoea 2/31 (6.5%) 
Ophthalmological system 4/31 (12.9%) 
Pigmentary retinopathy 2/31 (6.5%) 
Cataract 1/31 (3.2%) 
Megacornea 1/31 (3.2%) 
Haematological system 4/31(12.9%) 
Anaemia 4/31 (12.9%) 
Cardiovascular system 4/31 (12.9%) 
Left ventricular hypertrophy 2/31 (6.5%) 
Cardiomyopathy 1/31 (3.2%) 
Ventricular septal defect 1/31 (3.2%) 
Growth abnormalities 16/31 (51.6%) 
Failure to thrive 16/31 (51.6%) 
Microcephaly 5/31 (16.1%) 
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Table 2 Clinical, biochemical and radiological features of 31 patients with RRM2B 
deficiency. Abbreviations: COX cytochrome c oxidase, NAA N-Acetyl aspartate, NAG N-
acetyl beta-D glucosaminidase, RBP retinol binding protein, RRF ragged-red fibre, SDH 
succinate dehydrogenase.  
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FIGURE LEGENDS 
 
Figure 1a depicting the 9 exons (E1-9) of RRM2B mRNA showing the location of each of 
the variants identified in the 9 new patients (blue for new variants and green for previously 
reported variants). p53R2 comprises 351 amino acid residues. Each exon is labelled with the 
segment of the amino acid chain it encodes.  Variants in the 22 previously reported patients are 
indicated in black.  fs frameshift; * stop codon 
 
Figure 1b 3D structure of a RRM2B dimer depicting the location of new non-truncating 
variants observed in the new cases.  
The two subunits of the RRM2B dimer, taken from the reported structure (PDB code 3HF1), 
are shown in ribbon representation. The wild-type amino acids bearing the novel variants 
from this study are shown as sticks, coloured yellow (for missense changes) and cyan (for 
indel). The di-iron metal centre for one RRM2B subunit is represented by the two Fe atoms 
shown as spheres.     
 
Figure 2 Histopathological findings associated with RRM2B deficiency.  
The images show the histochemical and ultrastructural features of patients C, D, G and I. On 
haematoxylin and eosin staining (A, B, C, D), there were myopathic features, increased 
variation in fibre size with excess small fibres, and vacuoles. On Gömöri trichrome staining 
(E, F, G, H), there was accumulation of mitochondria in the vacuolated fibres and there were 
some ragged-red fibres. Lipid staining with oil red O (I, J, K, L) showed marked excess lipid 
in the vacuolated fibres. SDH histochemistry showed fibres with increased staining (M, N, O, 
P). Cytochrome oxidase showed frequent negative fibres in all four patients (Q, R, S, T). 
Electron microscopy was available in patients D, G and I and showed clusters of enlarged 
atypical mitochondria (U, V, W). Nemaline rods were also present (not illustrated) in patients 
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G and I. Patient D had two muscle biopsies 4 months apart, the second taken after a low-fat 
diet. The two biopsies were similar except for reduced lipid following the low-fat diet. All the 
images of this patient show the first biopsy except for panel N, which is from the second. The 
table summarises muscle biopsy findings for 8/9 new patients for whom this was available. 
Abbreviations: CoQ Coenzyme Q, COX cytochrome c oxidase, EM electron microscopy, 
NADH reduced nicotinamide adenine dinucleotide, ND Not done, RRF ragged-red fibre, 
RBF ragged-blue fibres, SDH succinate dehydrogenase. 
 
Figure 3 Kaplan-Meier Curve of survival of the 31-patient cohort of RRM2B-associated 
MDDS. 
The figure shows survival of 31 cases including 9 new cases from this cohort and 22 
previously published cases. 3-month survival was 64.5%, 6-month survival was 29%, 1-year 
survival was 16%, 2-year survival was 9.6%. 
 
 
